3.25 (-%)
As of Oct 31, 2024
Source:
Sutro Biopharma, Inc. is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF , and our site-specific conjugation platform, XpressCF+ . We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, dual conjugate ADCs, or ADC2s, and cytokine derivatives.
Country | United States |
Headquarters | south san francisco, california |
Phone Number | (650) 881-6500 |
Industry | manufacturing |
CEO | William J. Newell |
Website | www.sutrobio.com |